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Mother-infant transmission of hepatitis B virus (HBV) accounts for up to 30% of worldwide chronic
infections. The mechanism and high-risk period of HBV transmission from mother to infant are unknown.
Although largely prevented by neonatal vaccination, significant transmission continues to occur in high-risk
populations. It is unclear whether HBV can traverse an intact epithelial barrier to infect a new host. Trans-
placental transmission of a number of viruses relies on transcytotic pathways across placental cells. We wished
to determine whether infectious HBV can traverse a polarized trophoblast monolayer. We used a human
placenta-derived cell line, BeWo, cultured on membranes as polarized monolayers, to model the maternal-fetal
barrier. We assessed the effects of placental maturity and maternal immunoglobulin on viral transport.
Intracellular viral trafficking pathways were investigated by confocal microscopy. Free HBV (and infectious
duck hepatitis B virus) transcytosed across trophoblastic cells at a rate of 5% in 30 min. Viral transport
occurred in microtubule-dependent endosomal vesicles. Additionally, confocal microscopy showed that the
internalized virus traverses a monensin-sensitive endosomal compartment. Differentiation of the cytotropho-
blasts to syncytiotrophoblasts resulted in a 25% reduction in viral transcytosis, suggesting that placental
maturity may protect the fetus. Virus translocation was also reduced in the presence of HBV immunoglobulin.
We show for the first time that transcytosis of infectious hepadnavirus can occur across a trophoblastic barrier
early in gestation, with the risk of transmission being reduced by placental maturity and specific maternal
antibody. This study suggests a mechanism by which mother-infant transmission may occur.
Over 350 million people worldwide are chronically infected
with hepatitis B virus (HBV), with mother-infant transmission
accounting for up to 30% of cases (19). Congenital infection
results in chronic hepatitis in 90% of children and the risk of
liver failure or hepatocellular carcinoma and death in early
adult life. The incidence of in utero transmission of HBV is
unknown, as mother-to-infant transmission may occur prena-
tally, during delivery, or early postpartum. HBV has been
found in amniotic fluid, breast milk, and vaginal fluids, as well
as cord blood and infant gastric contents (7, 24). Maternal
HBeAg status is the most significant factor determining risk of
perinatal transmission, although maternal HBcAb-negative
status and high HBsAg titer have also been reported to in-
crease the risk of transmission (6, 61).
Vaccination of newborn infants reduces the likelihood of
perinatal transmission from HBeAg-positive mothers by 79 to
90% (2), and the likelihood is further reduced by concurrent
administration of HBV immunoglobulin (HBIG). While this
implies that most transmission probably occurs perinatally, a
clinically significant proportion of neonatal viral infection oc-
curs despite vaccination. Among children vaccinated at birth, a
1 to 5% viral transmission rate is reported (8, 9, 26, 45, 64).
Figures of vaccination failure rates from China are even higher
(51, 62), suggesting that in utero HBV transmission may be
more significant among high-risk groups. Additionally, infec-
tion risk has been related to the presence of DNA in the
placenta (61) and to maternal viremia (4, 38), supporting an
association between the state of maternal HBV during preg-
nancy and the risk of transmission to the baby. It is unclear
whether HBV can traverse intact epithelial barriers to infect
the fetus during gestation. HBV DNA has been found in re-
ducing of the concentrations from the maternal to the fetal
side of the placenta, suggesting cell-to-cell transfer of virus in
the placenta and a possible mechanism for in utero transmis-
sion (61, 63).
The placenta is made up of chorionic villi consisting of a
fetal capillary, villous stroma, and a layer of trophoblast cells
consisting of syncytiotrophoblasts and cytotrophoblasts. These
cells constitute a tight polarized epithelial monolayer compris-
ing tight junctions preventing lateral and paracellular diffusion
of substrates. Their apical surfaces are in contact with maternal
blood, while their basolateral surfaces are contiguous with the
fetal circulation. By 20 weeks, these cells terminally differen-
tiate and fuse to form multinucleated syncytiotrophoblasts
(44). The syncytiotrophoblast constitutes the maternal-fetal
barrier through which exchanges of substrates occur by trans-
cytosis (15). Infection of the placenta and of the fetus depends
on the permissiveness of these cells to the passage of patho-
gens. Maternal-fetal transmission of a number of viruses has
been shown, with various consequences for the baby (17, 22,
23, 31).
We examined the ability of infectious HBV to cross the
placenta in an in vitro system. Trophoblast-derived BeWo cells
grown on semipermeable inserts form a polarized monolayer
with tight junctions between cells as a model of the maternal-
fetal barrier (5). We show that these cells transcytose cell-free
HBV to a high degree in endosomes dependent on an intact
cellular cytoskeleton. Utilizing duck hepatitis B virus (DHBV)
as an infectious model, we confirmed that the transcytosed
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virus remains infectious. HBV transcytosis was reduced with
syncytiotrophoblast formation, as well as by specific antibody.
The findings of this study suggest that infectious HBV may be
able to transcytose across the maternal-fetal barrier in the first
trimester.
MATERIALS AND METHODS
Materials. HBV was obtained from the supernatant of HepG2 cells trans-
duced with Adeno-HBV (kind gift from J. Torresi, Melbourne, Australia).
DHBV (strain D16) was obtained by sucrose-cushion purification of serum from
infected ducklings. Brefeldin A, monensin, colchicine, and forskolin were pur-
chased from Sigma-Aldrich. HBIG was a kind gift from P. Angus, Melbourne,
Australia. Rabbit anti-ZO-1 antibody was purchased from Zymed. We purchased
Alexa 488, Alexa 568 secondary antibodies, and TOTO-3 from Molecular
Probes. [3H]inulin (1 mCi) was purchased from Amersham. HBV and DHBV
PCRs were performed with iQ SYBR Green Supermix (Bio-Rad) and primers
supplied by Geneworks, Australia.
Cell lines. BeWo cells were kindly provided by S. N. Breit, Sydney, Australia.
These cells were maintained in Dulbecco’s modified Eagle medium (Gibco) with
glutamine, high glucose supplemented with 10% fetal bovine serum, and 1%
penicillin and streptomycin. Cells were used between passages 5 and 15 and
seeded onto membranes at 1 105 cells  cm2. HepG2 cells were maintained in
minimal essential medium (Gibco) supplemented with 10% fetal bovine serum,
1% penicillin and streptomycin, and 1% glutamine. HepG2 cells grown on
75-mm cell culture flasks (BD Falcon) were transduced with Adeno-HBV and
cultured for 14 days before cell supernatants were collected, clarified by low-
speed centrifugation, and quantified for HBV by PCR. Adeno-HBV-transduced
HepG2 cells produce infectious HBV virions via all viral replicative intermedi-
ates (50).
Transcytosis studies. BeWo cells were seeded to 70% confluence on six-well
PET cell culture inserts, 1-m pore size (BD Falcon), in a two-chambered
system. In this system, BeWo cells form a polarized monolayer with tight junc-
tions between cells, allowing access to both the apical and basolateral domains.
Transepithelial resistance was measured daily at 37°C with a voltohmmeter
(Millipore, Australia), and the monolayer was determined to be polarized and
contiguous if corrected transepithelial resistance measurements exceeded 100
  cm2. Blank inserts with media were used to zero between measurements.
Cultures were not permitted to proceed for more than 5 days, to avoid over-
growth and cell layering. In addition, each transcytosis experiment included
[3H]inulin in the apical supernatant to calculate passive diffusion. Briefly, we
added 3.5 Ci/ml [3H]inulin apically, and 100-l aliquots of the collected sam-
ples were mixed with scintillation liquid and counted. Percent [3H]inulin diffu-
sion was calculated by comparing apical and basolateral levels, and we noted that
diffusion remained constant between culture plates. Virus (107 copies  ml1 of
HBV or 108 copies  ml1 of DHBV) was added to the apical domain of the
polarized monolayers, and all of the basolateral supernatant was collected at
(30-min) intervals and replaced with fresh warm medium. After three basolateral
collections in the absence of drug, transcytosis was inhibited by brefeldin A (1
g/ml), monensin (2 M), colchicine (5 M), or no drug. Drugs were adminis-
tered to the cells in both the apical and basolateral chambers at identical con-
centrations. During sample collection, supernatant was replaced with fresh me-
dium containing drugs. Apical supernatants were collected at the conclusion.
Percent transcytosis was determined by calculation of the progressive virus titer.
DHBV titration. Ethical approval for this study was granted by the AMREP
Animal Ethics Committee. Primary duck hepatocytes (PDH) were used to quan-
tify the infectious virus titer according to a modification of a previously described
method (1). PDH were prepared by collagenase perfusion of 7-day-old Pekin-
Aylesbury ducklings, as described previously (52). DHBV-negative PDH were
grown on glass coverslips for 48 h. Apical and basolateral supernatants from
BeWo transcytosis experiments were clarified by centrifugation. These were
serially diluted 10-fold in media and used to infect the hepatocytes in duplicate
wells. The inoculum was left on the cells for 24 h and then removed and replaced
with fresh medium. PDH were incubated for 7 days to allow infected foci to form.
Coverslips were then fixed and stained with 1H1 DHBV pre-S antibody and
visualized with Alexa 488 goat anti-mouse antibody. Foci were counted by flu-
orescence microscopy. An estimate of the infectious virus titer was determined
by the average of duplicate well counts, with correction for the dilution factor.
Quantitative PCR. Clarified apical and basolateral supernatants were treated
with proteinase K (Promega) for 30 min. PCR was then performed in 25-l
reactions in a thermal cycler (LightCycler; Bio-Rad) according to the SYBR green
protocol (Bio-Rad) using primers in the precore region of HBV, PC1 (GGGAGG
AGATTAGGTTAA) and PC2 (GGCAAAAACGAGAGTAACTC) (25), or
DHBV, DHBV03 (ACTAGAAAACCTCGTGGACT) and DHBV04 (GGGAGA
GG-GGAGCCCGCACG) (56). Standards of a known quantity of plasmid HBV
DNA were serially diluted in negative supernatant. Standards were processed in
parallel with samples and tested in duplicate with each run to provide a standard
curve for quantification.
Forskolin treatment. BeWo cells were seeded to 70% confluence onto cell
culture inserts and treated 24 h later with 80 M forskolin in the apical and
basolateral chambers. The cells were treated for 48 h before being thoroughly
washed and fresh medium applied. Forskolin-induced cAMP production leads to
terminal differentiation and fusion of BeWo cells to form syncytiotrophoblasts
(58) but will also inhibit cell division, as differentiated syncytiotrophoblast cells
do not divide. We had determined previously the ideal seeding density and
treatment durations to maximize cell fusion without compromise of monolayer
integrity from inhibition of cell division. Thus, we achieved BeWo monolayers
that were contiguous and comprised both fused and solitary cells. [3H]inulin
diffusion studies and transepithelial resistance measurements confirmed that the
monolayers were intact. Cells were then fixed and stained for ZO-1 antibody and
visualized with Alexa 488 and propidium iodide before examination by confocal
microscopy. The numbers of nuclei and cell boundaries were counted in multiple
fields, and their ratios were used to determine the percentage of cell fusion.
HBIG treatment. BeWo monolayers were treated with purified HBIG for 72 h
at 0, 100, or 1,000 mg/liter in both apical and basolateral supernatants. HBV was
added to the apical domain, and basolateral supernatant was collected every 30
min and replaced with medium containing HBIG to maintain the concentration
of HBIG throughout the experiment.
IgG ELISA. As most HBV hyperimmune globulin comprises immunoglobulin
G (IgG), the rate of transcytosis of HBIG across BeWo monolayers was deter-
mined by total IgG enzyme-linked immunosorbent assay (ELISA). A standard
curve was obtained by serial dilution of HBIG of known concentration. Immu-
nosorbent plates (Nunc) were coated with 100 l of 0.01% monoclonal anti-
human IgG Fc (Chemicon, Australia) in bicarbonate buffer. Plates were blocked
in 3% skim milk powder in phosphate-buffered saline. Next, 100-l samples were
added to each well and incubated at 37°C for 2 h. Plates were then washed and
conjugated with 100 l of 0.02% sheep anti-human IgG horseradish peroxidase
(Amersham) for 45 min at room temperature and detected with 100 l of 1%
3,3,5,5-tetramethylbenzidine buffer (Chemicon), with the reaction being termi-
nated with 2.5 M H2SO4 when color was visible. Absorbance was read at 450-nm
and 620-nm wavelengths.
Indirect immunofluorescence. BeWo cell monolayers used in the transcytosis
studies described above were fixed in 4% paraformaldehyde with 0.01% Triton
X-100 in phosphate-buffered saline after the final collection. Semipermeable
membranes on which the cells were growing for transcytosis experiments were
then excised from the inserts and adhered to glass slides to allow for immuno-
detection and microscopic visualization. Cells were stained with 1H1 (monoclo-
nal anti-pre-S DHBV antibody) (42) and rabbit anti-ZO-1 antibody (against the
tight junction protein, zonula occludens-1). Alexa 568 goat anti-mouse and 488
goat anti-rabbit antibodies were used for visualization, and nuclei were stained
with TOTO-3. Forskolin-treated BeWo cells were treated with anti-ZO-1 anti-
body as described above and visualized with Alexa 488 secondary antibody and
propidium iodide.
Microscopy. Immunofluorescence examination of PDH was performed with
an Olympus IX70 microscope. Images of BeWo monolayers were acquired with
a Bio-Rad MRC 1024 Nikon scanning confocal microscope with Lasersharp
software. An optimal z plane through the monolayer was selected for each field
to maximize visualization of the (apical) ZO-1 distribution while still detecting
some signal from the (basolateral) very bright nuclear staining. Single xy images
in this confocal plane were used. Raw TIFF images were processed with Adobe
Photoshop.
Data analysis. Data were imported from the primary sources into Microsoft
Excel for analysis. Duplicates samples were always used. The error values shown
in the results represent the standard error of the mean for each experiment. The
two-tailed Student t test was used to determine the significance of differences
between values. We accepted P values of 0.05 as significant.
RESULTS
HBV transcytoses across BeWo monolayers. Confluent mono-
layers of BeWo cells were grown on semipermeable mem-
branes, and medium containing cell-free HBV was added to
the apical domains. Three 30-min basolateral medium collec-
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tions were taken before and after the addition of drugs that
inhibit specific transcytotic pathways (see “Transcytosis stud-
ies,” above). To each culture, brefeldin A, monensin, colchi-
cine, or no drug was added. Transepithelial resistance of the
BeWo monolayers did not vary with the addition of virus or
drug (data not shown). Virus titer in the supernatants was
determined by quantitative PCR. Results are given as means of
pre- and posttreatment collections from duplicate wells. Per-
cent transcytosis was calculated for each time point, allowing
for progressive loss of virus from the apical to the basolateral
domain.
Five percent of apical HBV was efficiently transcytosed by
polarized trophoblasts in 30 min (Fig. 1). Transcytosis of cell-
free virus varied little in the no-treatment groups. The addition
of brefeldin A, an agent that disrupts both the Golgi and
endosomes (20, 30), markedly inhibited HBV transcytosis.
Likewise, monensin, a Na ionophore that inhibits endosomal
acidification (36), inhibited viral transcytosis from pretreat-
ment levels of over 4% transcytosis to 1.7% in 30 min. Disrup-
tion of the cellular cytoskeleton with colchicine (32) resulted in
a similar degree of marked inhibition of transcytosis. The de-
grees of inhibition from all of these agents were very similar,
suggesting that they all inhibit different aspects of a single
pathway. It appears from these data that cell-free HBV is
transported from the apical to the basolateral surface of BeWo
cells by transcytosis in endosomes and that these are reliant
upon cytoskeletal elements for traffic.
Viral transcytosis is inhibited at 4°C. To determine whether
virus was being transported by an active cellular process, the
temperature dependence of viral translocation was examined.
Monolayers of BeWo cells on membranes were incubated at
4°C for 1 h. At this temperature, energy-dependent cellular
functions are largely inhibited, but passive diffusion of mole-
cules should remain unaffected. DHBV and [3H]inulin were
added to the apical supernatant of the BeWo monolayers.
Basolateral collections of media were taken every 2 h, and cells
were then rapidly warmed to 37°C and further collections were
taken.
Figure 2A shows that at 4°C, with all cellular activity halted
but diffusion minimally affected, there was very little virus
detected in the basolateral supernatant. These cells, when
warmed to 37°C, transcytosed virus effectively, indicating the
energy dependence of viral transport. In addition, the rapid
rate of transcytosis upon warming suggests that the virus had
bound to cell surface molecules at 4°C, which are then inter-
nalized almost immediately upon cell warming. By contrast,
[3H]inulin diffusion was not temperature dependent and re-
mained at about 0.9% throughout the 4 h. In addition, the
markedly higher rate of transport of the much larger DHBV
virion than of the small, 5-kDa [3H]inulin molecule is indica-
tive of active transport of virus rather than diffusion. Transcy-
tosis of hepadnavirus in BeWo cells appears to occur through
a process that requires cellular metabolism and perhaps
through a receptor-mediated mechanism.
FIG. 1. Transcytosis of HBV across BeWo monolayers. BeWo cells
were grown on semipermeable membranes, and HBV was added to the
apical domain. Percent viral transcytosis before (black bars) and after
(gray bars) administration of trafficking inhibitors was analyzed by
PCR. Free HBV transcytosed at a rate of around 5% per 30 min.
Brefeldin A and monensin markedly reduced transcytosis by endoso-
mal inhibition. Transcytosis was also reduced by colchicine-induced
disruption of the cellular cytoskeleton.
FIG. 2. Transcytosis of DHBV across BeWo monolayers. DHBV
was added to the apical pole of membrane-grown polarized BeWo
monolayers. Virus titer was determined by quantitative PCR. (A) BeWo
monolayers were placed at 4°C, and transcytosis was measured for 2 h.
Cells were transferred to 37°C, and samples were taken for a further
2 h. Diffusion of [3H]inulin (circles) was also calculated. DHBV trans-
cytosis (squares) is inhibited at 4°C and recommences upon warming of
the cells, implying that an active cellular process is required. By con-
trast, inulin diffusion is constant and temperature independent.
(B) Transcytosis of DHBV before (black bars) and after (grey bars) the
addition of drugs. DHBV was transcytosed by BeWo cells and was
affected by drugs similarly to HBV. DHBV apparently traffics by the
same route as HBV. *, P  0.02 (compared to no drug).
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Transcytosed virus is infectious. The internal pH of tran-
scytotic endosomes is acidic (around pH 5), promoting fusion
of the viral and endosomal membranes and thus releasing the
virus into the cytosol. HBV is an enveloped virus, and envel-
opment is necessary for its infectivity (57); thus, it was possible
that endocytosis of the HBV in BeWo cells would inactivate
the virus. In order to determine whether viral DNA transcy-
tosing through the BeWo monolayer consisted of infectious
virus particles, we utilized DHBV as an infectious model of
HBV. DHBV is very similar to HBV in structure and protein
functions (49) and has almost identical replication cycles (34).
Like all members of the hepadnavirus family, it is a hepato-
tropic, species-specific virus. In the absence of a readily avail-
able infectible cell culture system for HBV, DHBV serves as an
excellent and well-characterized infectious model (47).
Polarized BeWo cell monolayers grown on semipermeable
membranes were examined for DHBV transcytosis by PCR
and by infectious virus titer determined on virus-naı¨ve primary
duck hepatocytes. As described above, virus was added to cells
apically, and each monolayer was treated with trafficking in-
hibitors or with no drug.
DHBV transcytosed across the BeWo monolayer with effi-
ciency similar to that of HBV, and its passage was likewise
affected by transcytosis inhibitors. Virus transcytosis was inhib-
ited by monensin and colchicine similarly, suggesting that the
endosomes inhibited by monensin were reliant on microtubu-
lar function (Fig. 2A). We thus determined that DHBV was a
suitable model for examining the transcytosis of infectious
HBV in BeWo cells.
Infection of PDH with basolateral supernatant from BeWo
monolayers showed that transcytosis of DHBV through tro-
phoblasts does not affect its infectivity. Infectious hepadnavirus
transcytosed across BeWo monolayers at 3 to 5% per 30 min
(Fig. 3A). The infective viral titer was about 10-fold less than
total DNA by PCR, but the percentage of transcytosis re-
mained the same, indicating that the virus had not been altered
by its passage through the BeWo cells (Fig. 3A). As both
human and duck HBVs were transported across human tro-
phoblastic cells, it is likely that the pathway used by the viruses
is not host species or cell type specific.
Hepadnaviral traffic in BeWo cells. The inhibition of viral
transport with the various agents described above suggested
that a specific transcytotic route was taken by HBV in BeWo
cells. In order to differentiate the patterns of intracellular virus
distribution, cell monolayers used in the experiments described
above were fixed and stained for ZO-1 and DHBV for exam-
ination by confocal microscopy.
The BeWo cells were a single cell layer, with no overgrowth
and with tight junctions between the cells in a honeycomb
pattern characteristic of polarized epithelia (Fig. 4A). DHBV
immunostaining was visible at the level of the tight junctions,
indicating the presence of the virus at the apical surface. The
cytoplasmic distribution of the virus suggested accumulation in
vesicular structures (Fig. 3B). We notably did not see a perinu-
clear Golgi pattern of distribution of virus in brefeldin A-
treated cells, indicating that viral transport in BeWo cells
occurs independently of the Golgi and is likely via the transcy-
totic pathway (Fig. 3B) (27, 60). Monensin treatment led to
virus localizing to an area close to the apical surface of the cells
(Fig. 3B). This is probably the subapical compartment (SAC),
described for other epithelial cells as a sorting center directing
newly endocytosed substances to their plasma membrane des-
tinations (53). Also of note in the monensin-treated cells is that
there seems to have been minimal viral entry after the addition
of the drug, as very little cytoplasmic virus is evident. Colchi-
cine treatment led to cytoplasmic, widely distributed accumu-
lation of virus intracellularly (Fig. 3B). These results suggest
that hepadnavirus traffics from the apical surface to the SAC of
BeWo cells in microtubule-dependent endosomal vesicles be-
fore traveling to the basolateral surface and without recourse
to the Golgi, strongly suggestive of transcytosis as the mecha-
nism of transcellular transport.
HBV transcytosis is inhibited by cellular differentiation.
With placental development, trophoblasts differentiate and
fuse into multinucleated cells that form the syncytiotropho-
blast. The formation of this continuous barrier has been asso-
ciated with reduced viral transmission in some in vitro studies
(40, 41). We stimulated differentiation of BeWo cells with
forskolin, a potent inducer of cAMP (48). With differentiation,
cells fuse as they divide; however, terminally differentiated
cells will not further divide. Balancing these effects of cell
maturation, we generated cell monolayers that remained con-
tiguous but contained a significant proportion of terminally
differentiated syncytiotrophoblasts. We then added HBV to
FIG. 3. Transcytosed virus is infectious. Transcytosed DHBV was
used to infect PDH in serial dilution to determine infectious virus titer
by focus counting. (A) Actual virus titers in the basolateral supernatant
are given. Note the logarithmic scale. There is about 10-fold-less in-
fectious virus (gray bars) than total DNA (black bars), but the pro-
portions transcytosed remain the same. (B) Infectious DHBV particles
(circles) transcytose at approximately the same rate as total DNA
(squares) measured by PCR, 3 to 5% in 30 min.
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the apical medium, and basolateral collections were taken at
30-min intervals over several hours. [3H]inulin diffusion studies
ascertained the integrity of the monolayers. Cells were then
fixed, and intracellular tight junctions were stained with ZO-1
before examination by confocal microscopy to determine the
percentage of cell fusion.
Confocal microscopy revealed fusion of 3 to 10 cells within
a single cell boundary in cultures treated with forskolin (Fig.
5A). We determined a fusion rate of 21.0% ( 0.7%) in
treated cells. That is, on average, more than a fifth of the cells
were multinucleated. These monolayers did not transcytose
virus as effectively as untreated cells, resulting in a small but
statistically significant inhibition of transcytosis compared to
the untreated BeWo cells. Monolayers displaying differentia-
tion transcytosed only 4.4% of apically applied virus, compared
to 5.9% in undifferentiated cells (P 	 0.0168) (Fig. 5B). This is
a reduction in the rate of transcytosis of around 24%, close to
the cell fusion rate of 21%. The reciprocity between reduced
viral transport and cell fusion suggests that they are related.
Differentiation of the BeWo monolayer from mononuclear
cells with tight junctions to partial syncytiotrophoblast forma-
tion resulted in significant and proportional reduction in trans-
cytosis.
HBIG prevents HBV transcytosis. Antibodies against HBV
surface antigens are protective against disease. The presence
of high levels of HBV-specific antibody in infected mothers
may affect fetal infection. The effect of HBIG on the transcy-
tosis of HBV was studied. We used doses of HBIG based on
minimum target serum concentrations of antibody in liver
transplant patients receiving HBIG: approximately 100 mg/
liter (10, 21, 29). HBIG treatment at both 100 mg/liter and
1,000 mg/liter reduced HBV transcytosis by a modest but sig-
nificant degree compared to untreated cells and antibody-neg-
ative serum (P	 0.024) (Fig. 6). The addition of 10 times more
HBIG, however, caused little additional reduction in transcy-
tosis (P 	 0.71). The specificity of the action of the antibody
was determined by examining DHBV transcytosis in the pres-
ence of HBIG. HBV, but not DHBV, translocation was inhib-
ited by HBIG (Fig. 6).
Trophoblasts and BeWo cells are known to actively trans-
port IgG via the Fc receptor (12). In order to confirm that
BeWo cells were able to transcytose HBIG in this model, we
added HBIG to the apical domain of membrane-grown BeWo
cells and assayed the apical and basolateral supernatants for
IgG by ELISA. We found that BeWo cells transport 8% of
apically applied HBIG every 30 min (Fig. 6). This is a very high
rate of transcytosis and probably represents both active trans-
FIG. 4. Hepadnavirus traffic in BeWo cells. BeWo monolayers
used in the experiments reported in Fig. 2A were fixed in paraformal-
dehyde and stained for DHBV pre-S antigen (red) and ZO-1 (green).
Nuclei are blue. BeWo cells form a confluent, tight, polarized mono-
layer. (A) xz images show BeWo nuclei in a single layer. (B) In un-
treated BeWo cells (No Drug), intracellular DHBV is in vesicular
structures. Treatment with brefeldin A (Bref) did not result in accu-
mulation of the virus in a typical Golgi pattern. Monensin (Mon)
treatment led to virus accumulation in a discrete, subapical, non-Golgi
area of the cell, most likely the SAC. Little virus is seen elsewhere in
the cell. Endocytosis of further virus appears to have been inhibited by
monensin. Colchicine (Col)-induced disruption of microtubules inhib-
its endosomal transport, resulting in scattered virus throughout the
cell. Bar, 10 m.
FIG. 5. Syncytiotrophoblast formation inhibits transcytosis. BeWo
cells were grown to confluence on membranes in the presence of
forskolin. Fixed membranes were stained for ZO-1 (green). Nuclei are
red. (A) Untreated cells (No Drug) display honeycomb ZO-1 staining
of mononucleated BeWo cells; 21.0% ( 0.7%) of forskolin (FSK)-
treated cells fused to form multinucleated cells (arrows). Bar, 10 m.
(B) Transcytosis of HBV across the differentiated monolayer was as-
sessed, and virus titer was determined by quantitative PCR. The pres-
ence of differentiated cells in the monolayer significantly reduced
transcytosis of HBV (black bars) (*, P  0.02). Inulin diffusion (gray
bars) was not affected by cellular differentiation.
7204 BHAT AND ANDERSON J. VIROL.
 o
n
 N
ovem
ber 12, 2015 by University of Queensland Library
http://jvi.asm.org/
D
ow
nloaded from
 
port of the molecule and a response to a high apical load of
substrate.
It is likely that HBV formed complexes with Ig that were
saturated at 100 mg/liter, resulting in no further effect from
1,000 mg/liter of HBIG. The resultant virus-Ig complex may
have transcytosed at a reduced rate in these very actively trans-
porting cells. Thus, although we are able to detect viral DNA
by PCR in the basolateral domain, it is unclear whether, in fact,
this represents free virus and whether it remains infectious.
DISCUSSION
Although perinatal transmission accounts for up to 30% of
the carrier pool of HBV (19), very little is known about the
mechanism of viral transmission. Neonatal infection was com-
mon until the introduction of widespread targeted and univer-
sal HBV immunization of infants (59). The global initiative to
introduce world-wide vaccination programs will reduce the
number of chronically HBV-infected people, but vaccine fail-
ure rates are not insignificant. The factors determining vacci-
nation failure, including in utero HBV transmission, remain
unresolved.
Maternal-fetal transmission of a number of viruses by trans-
cytosis or infection of the placenta has been described. Human
immunodeficiency virus (HIV) transmission requires infected
lymphocytes to transmit virus by direct cell-to-cell contact with
the epithelial surface (3, 23). Unlike HIV and human T-cell
lymphotropic virus, however, which also readily cross BeWo
cells (23, 28), free HBV was able to enter these cells without
requiring cell association. In fact, free HIV can enter tropho-
blasts, but endocytosis leads to degradation of the virus rather
than transcytosis (54). Although trophoblasts are permissive
for cytomegalovirus (CMV) infection in vitro, modification of
the virus in uterine endothelial cells may be a requirement for
infection (13, 31). Replicating CMV also remains largely in the
cell, with some release through the apical, but not the baso-
lateral, surface (17), thus further protecting the fetus. By con-
trast, this study showed that transcytosis of infectious DHBV
across placental trophoblasts occurred without change to its
specific infectivity, and the same is thus likely to be true for
HBV, which showed very similar levels of transcytosis.
HBV entry most likely occurs by endosomal uptake at the
apical surface, and its temperature dependence suggests
strongly that it is an active process. Also, the rapid increase in
internalization upon warming from 4°C to 37°C is highly rem-
iniscent of receptor-mediated internalization. HIV has been
shown to travel through apical recycling endosomes to the
basolateral pole (54, 55). HBV appears to be transported from
the apical plasma membrane in microtubule-dependent endo-
somes to a subapically located site in the cell that is also
sensitive to monensin, likely the common endosome or SAC,
described for other polarized epithelial cells as a sorting center
for substrates. The dependence on microtubules is character-
istic of SAC-dependent, Golgi-independent trafficking (18).
Infectious virus is subsequently released from the basolateral
surface of trophoblasts into the fetal circulation.
At around 12 weeks of gestation, trophoblasts fuse and dif-
ferentiate into multinucleated syncytiotrophoblasts. We found
that a mixed population of cells did not transcytose virus as ef-
fectively as a monolayer of undifferentiated cells. This may be due
to changes in BeWo cellular protein expression accompanying
maturation that reduced virus attachment and transport (33,
35, 39, 43). As transport of molecules across the maternal-fetal
barrier must continue to take place throughout pregnancy, it is
likely that specific cell factors play a role in HBV transport and
that these change with cellular differentiation.
Maternal IgG protects the infant by its active transcytosis
across the placenta (11, 12). In some viral infections, such as
CMV and herpes simplex virus, the presence of maternal an-
tibodies is significant in protecting the fetus (14, 46). In others,
such as HIV, no identifiable protective antibodies have been
isolated to date. In Epstein-Barr virus infection, transmission
to the fetus may actually be enhanced by antibody-mediated
viral entry (16). The presence of maternal 
-HBc has been
associated with lower levels of perinatal transmission of HBV
(6). In addition, HBIG treatment of newborn infants helps
prevent transmission, underlying the role of passive immunity
in preventing disease acquisition. In our study, HBIG transcy-
tosed actively in BeWo cells. HBIG treatment of cells also
significantly and specifically reduced the rate of HBV transcy-
tosis and may have reduced its infectivity. The presence of
protective maternal antibodies transcytosing across the mater-
nal-fetal barrier with infectious virus may be one mechanism
limiting viral transmission in utero. Conversely, insufficient
maternal antibody levels may predispose to HBV transmission
during pregnancy.
In determining the factors that contribute to mother-infant
HBV transmission, the role of fetal development should be
considered. The fetus does not begin to develop a liver until
around 12 weeks of gestation (37). It is not known at what
stage the development of the functional enhancers and pro-
moters that allow the exclusively hepatotropic HBV to infect
hepatocytes takes place. We have shown that while HBV can
cross the pre-12-week maternal-fetal barrier, it appears that
this is less likely with trophoblast differentiation in later ges-
tation. Fetal hepatic immaturity may be how the fetus remains
protected from HBV; this possibility goes somewhat toward
FIG. 6. Effect of HBIG on transcytosis. BeWo cells were grown on
semipermeable membranes in the presence of HBIG for 72 h before
the addition of virus to the apical domain. Viral titers were determined
by quantitative PCR. Separately, HBIG alone was added to the apical
pole of BeWo monolayers to assess Ig transcytosis. HBIG significantly
reduced the transcytosis of HBV. This effect was not dose dependent
in this range. Values of significance are given in comparison to un-
treated controls (*, P  0.025). HBIG had no effect on the transpor-
tation of DHBV. HBIG itself was highly transcytosed by BeWo cells.
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explaining the efficacy of HBIG and HBV immunization at
birth in preventing infection.
This study addresses some key points regarding maternal-
fetal transmission of HBV. The virus is able to cross tropho-
blastic cells using the endosomal transport system and to remain
infectious. The high permeability of undifferentiated trophoblasts
to viral transcytosis suggests that early pregnancy is a potentially
high-risk period for viral transmission. Finally, these studies sug-
gest that some vaccine failures may represent infections ac-
quired in utero through transcytosis of HBV across the pla-
centa, and they propose one mechanism for mother-infant
transmission.
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